Four publications from the past week:
- Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis | link
- Preferences for a polygenic test to estimate cancer risk in a general Australian population | link
- Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer | link
- Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study | link
I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.